TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/05/24
TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024GlobeNewsWire • 02/28/24
TRACON Pharmaceuticals Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 TrialGlobeNewsWire • 12/20/23
TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront PaymentGlobeNewsWire • 11/20/23
TRACON Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/09/23
TRACON to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 9, 2023GlobeNewsWire • 10/31/23
TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as PlannedGlobeNewsWire • 09/18/23
TRACON Pharmaceuticals Announces Participation at Upcoming Investor ConferencesGlobeNewsWire • 09/05/23
TRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/14/23
TRACON to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 14, 2023GlobeNewsWire • 08/02/23
TRACON Pharmaceuticals to Present at the Maxim Group Healthcare Virtual ConferenceGlobeNewsWire • 06/16/23
TRACON Pharmaceuticals Announces Poster Presentations for Envafolimab and TRC102 at the 2023 ASCO Annual MeetingGlobeNewsWire • 05/30/23
TRACON Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/10/23